We are live on ! Find out more
CC

Checkpoint Capital Portfolio holdings

AUM $279M
1-Year Est. Return 45.74%
This Fund
S&P 500
This Quarter Est. Return
+39.48%
1 Year Est. Return
+45.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$298M
AUM Growth
+$83.9M
Cap. Flow
-$2.88M
Cap. Flow %
-0.97%
Top 10 Hldgs %
100%
Holding
11
New
3
Increased
4
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$9.82M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.31M
3
RVMD icon
Revolution Medicines
RVMD
+$8.31M
4
STOK icon
Stoke Therapeutics
STOK
+$3.63M
5
CORT icon
Corcept Therapeutics
CORT
+$3.5M

Top Sells

Rank Stock Value
1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$27.5M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$4.49M
3
SEPN
Septerna Inc
SEPN
+$3.98M
4
KYMR icon
Kymera Therapeutics
KYMR
+$2.04M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$54.1B
$111M 37.07%
150,000
+23
+0% +$15.2K
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$7.96B
$77.1M 25.84%
763,707
-296,293
-28% -$27.5M
CORT icon
3
Corcept Therapeutics
CORT
$12B
$32.6M 10.92%
392,331
+48,414
+14% +$3.5M
IRON icon
4
Disc Medicine
IRON
$2.97B
$28.4M 9.52%
430,000
+165,000
+62% +$9.82M
RVMD icon
5
Revolution Medicines
RVMD
$44B
$23M 7.7%
492,300
+212,300
+76% +$8.31M
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.92B
$10.8M 3.63%
+260,000
New +$8.31M
SEPN
7
Septerna Inc
SEPN
$1.75B
$5.33M 1.78%
283,158
-303,315
-52% -$3.98M
STOK icon
8
Stoke Therapeutics
STOK
$2.11B
$4.98M 1.67%
+212,049
New +$3.63M
KYMR icon
9
Kymera Therapeutics
KYMR
$8.94B
$3.5M 1.17%
61,750
-45,241
-42% -$2.04M
CYTK icon
10
Cytokinetics
CYTK
$10.4B
$2.07M 0.69%
+37,587
New +$1.55M
PTGX icon
11
Protagonist Therapeutics
PTGX
$9.44B
– –
-81,311
Closed -$4.49M

Similar funds

CB
Centennial Bank Conway, Arkansas $279M AUM 20.11% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
BWG
Balanced Wealth Group Westlake, Ohio $279M AUM 17.49% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Checkpoint Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Checkpoint Capital held 11 positions worth $298M, up 39% from $215M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Checkpoint Capital's Q3 2025 filing shows 3 new, 4 increased, 3 reduced and 1 closed positions. Its largest new stake was Crinetics Pharmaceuticals: 260,000 shares worth $10.8M. The largest sale was Rhythm Pharmaceuticals, an estimated $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Checkpoint Capital's largest Q3 2025 buy was Crinetics Pharmaceuticals: 260,000 shares worth $10.8M.
  • Checkpoint Capital added most to Disc Medicine in Q3 2025, an estimated $9.82M increase.
  • Checkpoint Capital's biggest Q3 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $27.5M.
  • Checkpoint Capital fully exited Protagonist Therapeutics in Q3 2025, selling an estimated $4.49M.
  • Checkpoint Capital's ten largest holdings make up 100% of its $298M portfolio in Q3 2025.
  • Checkpoint Capital opened 3 new positions and closed 1 in Q3 2025.
  • Checkpoint Capital's portfolio value rose 39% quarter-over-quarter to $298M.

Based on Checkpoint Capital's 13F filing for Q3 2025, filed 14 Nov 2025.